8 To 10 Amino Acid Residues In Defined Sequence Patents (Class 530/328)
-
Publication number: 20150140046Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.Type: ApplicationFiled: April 12, 2013Publication date: May 21, 2015Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
-
Publication number: 20150141347Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.Type: ApplicationFiled: May 22, 2013Publication date: May 21, 2015Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
-
Publication number: 20150141324Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.Type: ApplicationFiled: August 31, 2012Publication date: May 21, 2015Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Patent number: 9035023Abstract: To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an integer from 1 to 3 and n is an integer from 1 to 6.Type: GrantFiled: February 27, 2009Date of Patent: May 19, 2015Assignee: Piramal Imaging, SAInventors: Helmut Maecke, Jean Claude Reubi, Rosalba Mansi
-
Patent number: 9034824Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: July 3, 2014Date of Patent: May 19, 2015Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 9035024Abstract: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.Type: GrantFiled: April 12, 2013Date of Patent: May 19, 2015Assignee: University of MassachusettsInventors: Dario C. Altieri, Janet Plescia, Whitney Salz
-
Publication number: 20150133342Abstract: The present invention relates to mass spectrometry methods employing multiple reaction monitoring (MRM) in the field of cancer therapeutics, specifically prostate cancer and melanoma.Type: ApplicationFiled: May 3, 2013Publication date: May 14, 2015Inventors: Sun W. Tam, Ying Xu, Patrick J. Muraca
-
Publication number: 20150133367Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.Type: ApplicationFiled: April 26, 2013Publication date: May 14, 2015Inventor: Doron C. Greenbaum
-
Publication number: 20150132328Abstract: The present invention relates to the field of human and veterinary medicine. The invention solves the problem associated with the lack of an agent for improving the immune response in immunosuppressed individuals, or with autoimmunity problems as well as infections; reducing the effects of the stress, combating tissue fibrosis; the need for anti-inflammatory agents; treatments for acute and chronic hepatitis, treatments against malignant processes and metastasis, as well as thrombocytopenia, both in humans and animals. The present invention comprises a molecular complex formed by a metallic ion and a peptide as novel compound, which is denominated as an immunomodulator metallopeptide hereafter abbreviated as IMMP. Claims also include the process for obtaining the complex, the use of the metallopeptide for producing a therapeutic or nutraceutic agent, and the use of that agent in humans and animals.Type: ApplicationFiled: October 4, 2011Publication date: May 14, 2015Applicant: UNIVERSIDAD AUTONOMA DEL ESTADO DE MORELOSInventors: Jorge Alberto Reyes Esparza, Maria de Lourdes Rodriguez Fragoso, Ana Laura Badillo Jimenez, Lorena Julieta Torres Aguilar, Lorenzo Ulises Martinez Osuna, Abril Arianna Martinez De Los Rios Corsino, Carlos Antonio Arjona Canul, Hugo Morales Rojas
-
Publication number: 20150133305Abstract: The present invention is directed to methods, for example phage display assays, for bioengineering peptides that bind to individual distinct nucleotides. Also provided are peptides engineered by such methods. Specifically, cyclic peptides that bind individual distinct nucleotides are provided herein.Type: ApplicationFiled: November 7, 2008Publication date: May 14, 2015Inventors: Mineo Yamakawa, Joseph V. Kosmoski, Deane C. Little
-
Publication number: 20150133630Abstract: An object of the present invention is to provide molecules that bind to a target molecule in a pH dependent manner and a screening method for selecting such molecules. Provided is a screening method for selecting peptides that bind to a target molecule at a first pH and do not bind thereto at a second pH, including a step of preparing a peptide library in which each mRNA contains at least one special amino acid that undergoes a pH-dependent change in the charge of the side chain thereof, a step of bringing the peptide library into contact with the target molecule and incubating them under the first pH condition and selecting peptides that bind to the target molecule, and a step of selecting, from the peptides which have bound to the target molecule, peptides that do not bind to the target molecule under the second pH condition.Type: ApplicationFiled: June 6, 2013Publication date: May 14, 2015Applicant: The University of TokyoInventors: Hiroaki Suga, Takeo Iida
-
Publication number: 20150132219Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.Type: ApplicationFiled: May 3, 2013Publication date: May 14, 2015Inventors: Andreas Kjaer, Morten Persson, Michael Ploug
-
Patent number: 9029321Abstract: Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.Type: GrantFiled: March 30, 2012Date of Patent: May 12, 2015Assignee: Board of Regents of the University of TexasInventors: Mikhail G. Kolonin, Alexes Daquinag, Yan Zhang
-
Patent number: 9029502Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.Type: GrantFiled: December 19, 2011Date of Patent: May 12, 2015Assignee: The Regents of the University of MichiganInventors: Mukesh K. Nyati, Theodore S. Lawrence
-
Patent number: 9029327Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: GrantFiled: July 23, 2010Date of Patent: May 12, 2015Assignee: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Patent number: 9029329Abstract: The invention relates to peptidic compounds of general formula (I) R1-(AA)n-X1-X2-Ile-Gln-Ala-Cys-Arg-Gly-X3-(AA)p-R2 as caspase-14 activators. The invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically acceptable medium, and to the use of said composition for preventing and/or repairing damage to deoxyribonucleic acid, for preventing and/or treating cutaneous signs of ageing and photo-ageing, and for improving the skin barrier function. The invention further relates to a cosmetic treatment method for preventing and/or treating cutaneous signs of ageing and photo-ageing, and for preventing and/or repairing damage caused by ultraviolet radiation.Type: GrantFiled: February 1, 2011Date of Patent: May 12, 2015Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20150125477Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: November 3, 2014Publication date: May 7, 2015Inventors: Sabrina KUTTRUFF-COQUI, Toni WEINSCHENK, Jens FRITSCHE, Steffen WALTER, Norbert HILF, Oliver SCHOOR, Colette SONG, Harpreet SINGH
-
Publication number: 20150126457Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.Type: ApplicationFiled: April 17, 2013Publication date: May 7, 2015Inventors: Dennis J. Goebel, John Marshall
-
Publication number: 20150126456Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 6, 2013Publication date: May 7, 2015Inventors: Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
-
Publication number: 20150126441Abstract: Nutritive proteins comprising no phenylalanine (Phe) are provided. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present a benchmark protein.Type: ApplicationFiled: March 15, 2013Publication date: May 7, 2015Inventors: David Arthur Berry, Brett Adam Bohigian, Nathaniel W. Silver, Michael J. Hamill, Geoffrey von Maltzahn, John F. Kramarczyk, Rajeev Chillakuru
-
Publication number: 20150125482Abstract: The invention relates to a recombinant polypeptide construct comprising epitopes from Plasmodium falciparum protein circumsporozoite protein (CSP). The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8+ T-cell response. The polypeptides can be incorporated into immunogenic formulations against malaria. Additionally, the antigens are useful for facilitating evaluation of immunogenicity of candidate malaria vaccines.Type: ApplicationFiled: November 1, 2013Publication date: May 7, 2015Inventors: Martha Sedegah, Thomas Richie
-
Publication number: 20150125478Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: December 5, 2014Publication date: May 7, 2015Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffan WALTER, Harpreet SINGH
-
Publication number: 20150126432Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.Type: ApplicationFiled: May 9, 2013Publication date: May 7, 2015Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
-
Publication number: 20150126450Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.Type: ApplicationFiled: April 16, 2013Publication date: May 7, 2015Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
-
Patent number: 9023803Abstract: The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.Type: GrantFiled: June 1, 2011Date of Patent: May 5, 2015Assignee: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Toni Weinschenk, Steffen Walter
-
Patent number: 9023957Abstract: The present invention generally relates to processes and methods of peptide and protein synthesis. The present invention also relates to specific compounds for use in such processes and methods. It is shown herein that peptides with a C-terminal tertiary N,N-bis(2-mercaptoethyl)-amide (BMEA) undergo N-to-S acyl transfer at weakly acidic pH to form a transient thioester which can be captured for direct ligation with a cysteinyl peptide. These C-terminal BMEA peptides are easily prepared with standard Fmoc solid-phase synthesis protocols, thus giving a very convenient access to the thioester components for native chemical ligation.Type: GrantFiled: July 6, 2011Date of Patent: May 5, 2015Assignee: Nanyang Technological UniversityInventor: Chuan Fa Liu
-
Publication number: 20150121569Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.Type: ApplicationFiled: July 1, 2014Publication date: April 30, 2015Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNITERSITE PAUL SABATIER TOULOUSE IIIInventors: Jean-Philippe COMBIER, Dominique LAURESSERGUES, Guillaume BECARD, Francois PAYRE, Serge PLAZA, Jerome CAVAILLE, Jerome CAVAILLE
-
Publication number: 20150118286Abstract: Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Preferred octapeptide sequences are internally rich in tryptophan and/or tyrosine or arginine. The present invention is further directed to kits and compositions containing the present peptides, and methods of treatment of conditions involving expression of tyrosinase, in which the present peptides are administered topically for the treatment of conditions involving melanocyte activity in the skin.Type: ApplicationFiled: May 10, 2012Publication date: April 30, 2015Applicant: Elixir Institute of Regenerative MedicineInventors: Basil M. Hantash, Anan Abu Ubeid
-
Publication number: 20150118213Abstract: The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin.Type: ApplicationFiled: October 21, 2014Publication date: April 30, 2015Inventors: Nadav Orr, Yair Pilpel, Sivan Doron
-
Publication number: 20150119334Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.Type: ApplicationFiled: June 3, 2013Publication date: April 30, 2015Applicant: Ben-Gurion niversity of the Negev Research and Development AuthorityInventors: Hanna Rapaport, Anna Gittelman
-
Publication number: 20150119340Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.Type: ApplicationFiled: October 29, 2014Publication date: April 30, 2015Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
-
Publication number: 20150118698Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.Type: ApplicationFiled: May 4, 2012Publication date: April 30, 2015Applicant: Nordic Biociences A/SInventors: Natas[c]ha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming
-
Publication number: 20150119336Abstract: The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine.Type: ApplicationFiled: April 5, 2013Publication date: April 30, 2015Inventors: Dieter Willbold, Susanne Aileen Funke, Oleksander Brener, Luitgard Nagel-Steger, Dirk Bartnik
-
Patent number: 9018351Abstract: The present invention relates to an anti-tenascin C peptide aptamer having a specific amino acid sequence and a diagnosis kit comprising it. The anti-tenascin C peptide aptamer of the instant invention shows a predominant clearance rate due to its small molecular weight as well as specific binding affinity to tenascin C, having excellent advantages in in vivo or ex vivo tumor imaging.Type: GrantFiled: July 31, 2013Date of Patent: April 28, 2015Assignee: Industry-Academy Cooperation Foundation, Dankook UniversityInventors: Sun Joo Jeong, Mee Young Kim, Ok Ran Kim, Heui Ran Lee, Kee Rang Park
-
Publication number: 20150110744Abstract: There is provided peptides for inhibiting growth of cancer cells, the peptides comprising the amino acid sequence RxKxKxxxxR wherein K and R are respectively lysine and arginine amino acid residues, each x is independently an amino acid, and 5 wherein the peptide has 50% or less amino acid sequence identity with the amino acid sequence RSKAKNPLYR (SEQ ID. No. 2). Each x amino acid may independently be an amino acid residue selected from the group consisting of alanine (A), valine (V), leucine (L), isoleucine (I), threonine (T) and serine (S) amino acid residues. There is also provided chimeric proteins incorporating a peptide of the amino acid sequence 10 RxKxKxxxxR, nucleic acids encoding for the peptide, expression vectors including a nucleic acid encoding the peptide for expression of the peptide, and methods for use of the peptide for inhibiting growth of cancer cells.Type: ApplicationFiled: January 24, 2013Publication date: April 23, 2015Inventor: Michael Valentine Agrez
-
Publication number: 20150112044Abstract: Methods to synthesize self-assembling peptides embedded with complex organic electronic subunits are provided.Type: ApplicationFiled: October 27, 2014Publication date: April 23, 2015Inventors: John D. Tovar, Allix M. Sanders
-
Publication number: 20150112043Abstract: A peptide including 8 animo acids having a sequence of cNGEGQQc, where c represents d-cysteine (Cys), N represents L-Asparagine (Asn), G represents L-Glycine (Gly), E represents L-Glutamic acid (Glu), and Q represents L-Glutamine (Gln).Type: ApplicationFiled: October 27, 2014Publication date: April 23, 2015Inventors: Linlang GUO, Guiping LI, Zhenzhu CHEN, Yajie LIU
-
Patent number: 9011816Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.Type: GrantFiled: March 25, 2011Date of Patent: April 21, 2015Assignee: Case Western Reserve UniversityInventors: Zheng-Rong Lu, Xueming Wu
-
Patent number: 9012403Abstract: The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present invention are useful in the treatment and prevention of diseases or disorders associated with a localized or systemic breakdown of epithelial and endothelial barrier functions. Particular diseases and disorders to be treated and/or prevented with the peptides or other compounds, methods and uses provided herein are burns, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ventilator induced lung injury (VILI), systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI), sepsis, multiorgan dysfunction syndrome (MODS), or edema.Type: GrantFiled: June 17, 2011Date of Patent: April 21, 2015Assignee: XiberScience GmbHInventors: Peter Petzelbauer, Sonja Reingruber
-
Publication number: 20150105334Abstract: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.Type: ApplicationFiled: September 22, 2014Publication date: April 16, 2015Inventor: Angel PORGADOR
-
Publication number: 20150104458Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.Type: ApplicationFiled: August 26, 2014Publication date: April 16, 2015Applicant: Biomay AGInventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20150104485Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.Type: ApplicationFiled: April 16, 2013Publication date: April 16, 2015Applicant: LUBRIZOL ADVANCED MATERIALS, INC.Inventors: Jose Maria Garcia Anton, Antonio Vicente Ferrer Montiel, Cristina Carreño Serraïma, Raquel Delgado González, Juan Cebrián Puche
-
Publication number: 20150105316Abstract: This application describes compounds acting as, for example, ?-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.Type: ApplicationFiled: December 22, 2014Publication date: April 16, 2015Inventors: Dennis Yamashita, Xiao-Tao Chen
-
Publication number: 20150105335Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.Type: ApplicationFiled: October 3, 2014Publication date: April 16, 2015Inventor: Richard Franklin
-
Publication number: 20150104472Abstract: Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X4WX5YX6 as defined herein and compositions comprising such are also provided. Methods of treating autoimmune disorders are provided.Type: ApplicationFiled: July 15, 2014Publication date: April 16, 2015Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventor: Betty A. Diamond
-
Publication number: 20150105327Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.Type: ApplicationFiled: October 14, 2014Publication date: April 16, 2015Inventors: Woojin An, Nouri Neamati, Kyunghwan Kim
-
Publication number: 20150104413Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.Type: ApplicationFiled: January 14, 2013Publication date: April 16, 2015Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Annamalai Selvakumar
-
Patent number: 9006404Abstract: Provided herein are compositions and methods for selectively targeting an endometriosis cell.Type: GrantFiled: December 26, 2006Date of Patent: April 14, 2015Assignees: Sanford-Burnham Medical Research Institute, Keio UniversityInventors: Michiko Fukuda, Daisuke Aoki, Noriko Nozawa
-
Patent number: 9006183Abstract: The use of lipopeptides as inducers of NF-?B for the protection of mammals from the effects of apoptosis is described.Type: GrantFiled: July 15, 2013Date of Patent: April 14, 2015Assignees: Cleveland Clinic Foundation, Cleveland BioLabs, Inc.Inventors: Alexander Shakhov, Andrei Gudkov
-
Patent number: 9000125Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.Type: GrantFiled: May 11, 2012Date of Patent: April 7, 2015Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische